Tag: Endospan
Vascular News’ top 10 most popular stories of October 2024
Vascular News' live conference coverage, an interview with Kevin Mani (Uppsala University Hospital, Uppsala, Sweden), and several industry updates feature in October's top 10.
1....
Endospan completes enrolment of primary arm in TRIOMPHE IDE clinical study
Endospan today announced the completion of enrolment for the primary arm of its TRIOMPHE investigational device exemption (IDE) clinical study investigating the Nexus aortic...
Vascular News’ top 10 most popular stories of July 2024
Several company updates including Series A funding for Endoron Medical, new insights on the role of machine learning in determining endovascular aneurysm repair (EVAR)...
Endospan releases early TRIOMPHE IDE study results at Society of Thoracic...
Endospan shared 30-day results from the first 22 patients enrolled in the TRIOMPHE investigational device exemption (IDE) study in a late-breaking presentation at the...
Endospan announces initial experience with the custom-made Nexus Duo aortic arch...
Endospan has announced the initial experience with its custom-made Nexus Duo aortic arch stent graft system. Theodosios Bisdas (Athens Medical Centre, Athens, Greece) presented...
Endospan enrols first patient in the TRIOMPHE IDE study
Endospan has announced the first implant of its Nexus aortic arch stent graft system on a patient in Norfolk, USA, with a thoracic aortic...
Aortic Arch Solutions: E-vita OPEN NEO and NEXUS
NOTE: This supplement is only available to read in selected countries and geographies
In this supplement, sponsored by CryoLife:
Augusto D’Onofrio, Giorgia Cibin, and Michele...
FDA grants Endospan IDE approval to initiate Nexus study
The US Food and Drug Administration (FDA) has granted Endospan an investigational device exemption (IDE) to start the TRIOMPHE study on the Nexus aortic...
FDA grants Nexus aortic arch stent graft system breakthrough designation
Endospan was recently granted breakthrough device designation from the US Food and Drug Administration (FDA) for the Nexus aortic arch stent graft system.
The FDA’s...
VIVA 2019: Nexus stent graft demonstrates promising mid-term results
Positive two-year results from a prospective multicentre premarket study including 25 patients treated with the Nexus aortic arch stent graft (Endospan) were presented today...
CryoLife enters into strategic distribution agreement with Endospan
According to a press release, Cryolife has entered into strategic distribution and credit facility agreements with Endospan. Under the terms of the agreement, CryoLife...
Endospan secures CE mark approval for branched endovascular aortic arch repair...
Endospan has announced that it has received CE mark for its Nexus stent graft system, to be used for branched endovascular repair in the...
Endospan elects Jeff Elkins as a director
Endospan, a company developing off-the-shelf endovascular repair of Aortic Arch Disease including aneurysms and dissections, has announced that it has elected Jeff Elkins to its board of...
Horizon stent graft receives CE mark
The Horizon stent graft system, developed to treat abdominal aortic aneurysms, has received CE mark. The stent graft system is produced by Endospan, a...
Mario Lachat: The Horizon and Nexus stent grafts in theory and...
Vascular News speaks to Mario Lachat, University of Zurich, Zurich, Switzerland, at the 2016 VEITHSymposium, about the concepts behind the Horizon and Nexus stent...
